Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022
July 26, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, July 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at...
Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global...
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
May 10, 2022 16:01 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the...
CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
May 09, 2022 09:15 ET
|
Amicus Therapeutics, Inc.
1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and...
Amicus Therapeutics Announces First Quarter 2022 Financial Results
May 09, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 ...
Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference
May 04, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare...
Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
April 26, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30...
Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038
April 19, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
March 16, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk and Forced Vital Capacity for ERT-Naïve and ERT-Experienced Patients Out to 3 Years Consistent Reduction in Biomarkers Continue...
Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference
March 10, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will...